The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2017 | How can we treat elderly patients with AML?
Wolfgang Hiddemann, MD, PhD, from Ludwig-Maximilians University, Munich, Germany, provides us an insight into the difficulties faced in treating elderly patients with acute myeloid leukemia (AML), who are not fit enough to be treated with intensive chemotherapy. A potential treatment that may be developed further in research, as suggested by Prof. Hiddemann, is the combination of the Bcl2 inhibitor, venetoclax, with hypomethylating agents, which have been proven in clinical trials to have had promising results in the elderly AML patient group. This interview was filmed at the European Hematology Association (EHA) 2017 Annual Congress in Madrid, Spain.
